Ember Therapeutics

Ember Therapeutics emerged from Monash University's biotech incubator with proprietary base-editing techniques that reduce off-target effects in rare disease treatment. The team has published in top-tier journals and secured partnerships with major pharmaceutical CROs. They're currently conducting preclinical studies on three lead candidates.